No evidence that patents are acting as a barrier to covid research, says Bristol Myers IP head
Pharma giant’s deputy general counsel Henry Hadad reflects on how work has changed during the pandemic and why more still needs to be done on 101 reform
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.